Factors affecting adherence to disease-modifying therapies in multiple sclerosis: systematic review
F Washington, D Langdon - Journal of neurology, 2022 - Springer
People with multiple sclerosis (MS) face challenges adhering to disease-modifying drug
(DMD) treatment. Poor adherence to treatment reduces its clinical effectiveness which can …
(DMD) treatment. Poor adherence to treatment reduces its clinical effectiveness which can …
Facilitating medication adherence in patients with multiple sclerosis
G Remington, Y Rodriguez, D Logan… - … journal of MS care, 2013 - meridian.allenpress.com
This article reviews adherence to medication in multiple sclerosis (MS) patients from the
perspective of nurse and social worker authors. It reviews data on patient adherence and …
perspective of nurse and social worker authors. It reviews data on patient adherence and …
Real-world adherence and persistence to oral disease-modifying therapies in multiple sclerosis patients over 1 year
KM Johnson, H Zhou, F Lin, JJ Ko, V Herrera - Journal of Managed Care & …, 2017 - jmcp.org
BACKGROUND: Disease-modifying therapies (DMTs) are indicated to reduce relapse rates
and slow disease progression for relapsing-remitting multiple sclerosis (MS) patients when …
and slow disease progression for relapsing-remitting multiple sclerosis (MS) patients when …
Impact of medication adherence to disease-modifying drugs on severe relapse, and direct and indirect costs among employees with multiple sclerosis in the US
JI Ivanova, RE Bergman, HG Birnbaum… - Journal of medical …, 2012 - Taylor & Francis
Objective: To compare rates of severe relapse and total direct and indirect costs over a 2-
year period between US-based employees with multiple sclerosis (MS) who were adherent …
year period between US-based employees with multiple sclerosis (MS) who were adherent …
Adherence to disease modifying drugs among patients with multiple sclerosis in Germany: a retrospective cohort study
K Hansen, K Schüssel, M Kieble, J Werning, M Schulz… - PloS one, 2015 - journals.plos.org
Background Long-term therapies such as disease modifying therapy for Multiple Sclerosis
(MS) demand high levels of medication adherence in order to reach acceptable outcomes …
(MS) demand high levels of medication adherence in order to reach acceptable outcomes …
Comparison of adherence and persistence among multiple sclerosis patients treated with disease-modifying therapies: a retrospective administrative claims analysis
R Halpern, S Agarwal, C Dembek, L Borton… - Patient preference …, 2011 - Taylor & Francis
Purpose: To compare adherence and persistence among patients with multiple sclerosis
(MS) initiated on disease-modifying therapy (DMTs), including intramuscular (IM) interferon …
(MS) initiated on disease-modifying therapy (DMTs), including intramuscular (IM) interferon …
An evaluation of adherence in patients with multiple sclerosis newly initiating treatment with a self-injectable or an oral disease-modifying drug
Objective As the multiple sclerosis (MS) disease-modifying drug (DMD) treatment options
have expanded to include oral therapies, it is important to understand whether route of …
have expanded to include oral therapies, it is important to understand whether route of …
[HTML][HTML] Adherence and persistence to drug therapies for multiple sclerosis: a population-based study
C Evans, RA Marrie, F Zhu, S Leung, X Lu… - Multiple Sclerosis and …, 2016 - Elsevier
Objective We aimed to estimate the prevalence and predictors of optimal adherence and
persistence to the disease-modifying therapies (DMT) for multiple sclerosis (MS) in 3 …
persistence to the disease-modifying therapies (DMT) for multiple sclerosis (MS) in 3 …
Impact of increasing adherence to disease-modifying therapies on healthcare resource utilization and direct medical and indirect work loss costs for patients with …
S Yermakov, M Davis, M Calnan, M Fay… - Journal of medical …, 2015 - Taylor & Francis
Objectives: To estimate the effect of adherence to disease-modifying therapies (DMTs)
among patients with multiple sclerosis (MS) on healthcare resource utilization (HRU) and …
among patients with multiple sclerosis (MS) on healthcare resource utilization (HRU) and …
Adherence to multiple sclerosis disease-modifying therapies in Ontario is low
Background/Objective: Differences in patient adherence to various disease-modifying drugs
(DMDs) in the treatment of multiple sclerosis (MS) are not well understood. The goal of this …
(DMDs) in the treatment of multiple sclerosis (MS) are not well understood. The goal of this …